LakeShore Biopharma CoLSBCF Return-on-Tangible-Equity is -49.49% as of Mar. 2025. Among 1,205 Biotechnology companies, LakeShore Biopharma Co ranks better than 62.99% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. LakeShore Biopharma Co's annualized net income for the quarter that ended in Mar. 2025 was $-33.26 Mil. LakeShore Biopharma Co's average shareholder tangible equity for the quarter that ended in Mar. 2025 was $67.21 Mil. Therefore, LakeShore Biopharma Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 was -49.49%.
The historical rank and industry rank for LakeShore Biopharma Co's Return-on-Tangible-Equity or its related term are showing as below:
LSBCF's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.47 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
LakeShore Biopharma Co (OTCPK:LSBCF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
LakeShore Biopharma Co Return-on-Tangible-Equity Related Terms
LakeShore Biopharma Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for LakeShore Biopharma Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LakeShore Biopharma Co Return-on-Tangible-Equity Chart
LSBCF vs ACUT, PPCB, ENSC: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, LakeShore Biopharma Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LakeShore Biopharma Co Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where LakeShore Biopharma Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -49.49% mean?
LakeShore Biopharma Co (LSBCF) has a Return-on-Tangible-Equity of -49.49% as of Mar. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on LakeShore Biopharma Co and its competitors. According to the industry distribution chart, LakeShore Biopharma Co ranks #446 out of 1205 companies in the Biotechnology industry, placing it in the top 37%.
Is LakeShore Biopharma Co's Return-on-Tangible-Equity too high?
LakeShore Biopharma Co's current Return-on-Tangible-Equity is -49.49%. Based on the distribution chart, LakeShore Biopharma Co ranks #446 out of 1205 companies in the Biotechnology industry, which is above the industry midpoint.
How does LakeShore Biopharma Co's Return-on-Tangible-Equity compare to ACUT and PPCB?
According to the Biotechnology industry distribution chart, LakeShore Biopharma Co ranks #446 out of 1205 companies for Return-on-Tangible-Equity. This puts LakeShore Biopharma Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on LakeShore Biopharma Co and its competitors. LakeShore Biopharma Co's current Return-on-Tangible-Equity is -49.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Return-on-Tangible-Equity of -49.49%. The current Return-on-Tangible-Equity is -49.49%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Return-on-Tangible-Equity is -49.49% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSBCF has been successfully added to your 